Animal Pharm is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer makes changes to US animal health leadership

Boehringer Ingelheim's president and chief executive of operations in the US will retire at the end of the year, after 15 years at the firm. 

Paul Fonteyne is being replaced by Wolfgang Baiker on March 1, 2018. Boehringer's US president and chief executive oversees both human and animal health.

Dr Baiker joined Boehringer in 1989. This is the first time he will work as part of the animal health management team. He has previously served in numerous senior leadership roles across international project management, global development and biopharmaceuticals

Dr Baiker is currently Boehringer's senior vice president of human pharma supply and global quality, as well as head of the biopharma unit.

Until the end of the year, Mr Fonteyne will carry on in a separate role – president of animal health. In this position, he will continue to oversee the integration of operations following the Merial acquisition. Boehringer told Animal Pharm the successor to the position of US president of animal health will be announced at a later time.

Mr Fonteyne has been the head of Boehringer's US operations since 2011. He previously worked for Merck and Abbott Laboratories.

The previous president of animal health in the US was Albrecht Kissel, who recently assumed the role of global head of commercial operations for the animal health business and will be based at the firm's global headquarters in Ingelheim, Germany.

After the Merial merger closed in 2017, Boehringer announced its new management team – drawing from both sides of the transaction. 

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AP013605

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel